Angioedema News

January 13, 2022January 14, 2022

Takeda Canada Seeks AI, Digital Solutions With Innovation Challenge

Angioedema News

With a goal of finding new digital technologies and artificial intelligence (AI) solutions for patients with rare genetic disorders like hereditary angioedema (HAE), and for inflammatory bowel diseases, Takeda Canada ... Read more

January 10, 2022January 10, 2022

New Gene Mutation Linked to HAE Type 1 Identified in Spanish Family

Angioedema News

A new mutation in the SERPING1 gene linked to hereditary angioedema (HAE) type 1 was identified in three of five members of a Spanish family. Results were published in a letter to ... Read more

January 6, 2022January 6, 2022

HAE Patients Have High Rate of Cancer, Canadian Study Suggests

Angioedema News

People with hereditary angioedema (HAE) commonly have histories of cancer, which raises the possibility that it might predispose a person to develop cancer. These findings were reported in the study ... Read more

January 3, 2022January 4, 2022

Certain Conditions Found to Increase Risk of Angioedema in Older Adults

Angioedema News

Excess blood levels of uric acid — a normal body waste product — and Hashimoto’s disease, an autoimmune condition, may increase the risk of angioedema without hives for older adults, ... Read more

December 30, 2021December 30, 2021

Pharming, Sanofi Extend Partnership to Manufacture Ruconest

Angioedema News

Pharming Group and Sanofi have renewed an agreement for the manufacturing of Ruconest (conestat alfa), Pharming’s approved treatment for swelling attacks in people with hereditary angioedema (HAE). The two companies ... Read more

December 23, 2021December 23, 2021

Upper Airway Attacks Mostly Occur in Patients Ages 20-30, Smokers

Angioedema News

Swelling attacks affecting the airway usually occur in hereditary angioedema patients between the ages of 20 and 30 — and are more frequent among smokers, a study shows. However, the ... Read more

December 20, 2021December 20, 2021

Prepare to Light Up Buildings for Rare Disease Day 2022

Angioedema News, COVID-19 News

The National Organization for Rare Disorders (NORD) asks Americans to plan ahead to participate in the Light Up for Rare campaign to raise awareness of rare diseases. NORD is the ... Read more

December 16, 2021December 16, 2021

Trial of HAE Gene-editing Therapy NTLA-2002 Doses Its First Patient

Angioedema News

The first participant has been dosed in a Phase 1/2 clinical trial that is testing Intellia Therapeutics’ gene-editing therapy, NTLA-2002, in people with hereditary angioedema (HAE). “With the progress of our ... Read more

December 13, 2021December 13, 2021

2 Family Members Make Swift Switch to Oral Orladeyo Successfully

Angioedema News

Switching from under-the-skin injections to oral pills of Orladeyo (berotralstat), a preventive treatment, can be done without the need to taper prior therapy or go through complex regimens, according to ... Read more

December 9, 2021December 9, 2021

Highly Unpredictable Rate of Annual Attacks Seen in Certain Patients

Angioedema News

Over a third of hereditary angioedema patients continue to experience an unpredictable rate of annual attacks, including those on long-term preventive therapy, a retrospective analysis shows. These findings highlight the ... Read more

December 6, 2021December 7, 2021

Acute Allergic Angioedema in Woman, 81, Likely Triggered by Effexor XR

Angioedema News, COVID-19 News

Effexor XR (venlafaxine), a medication normally used to treat depression and anxiety, might have triggered acute allergic angioedema in an 81-year-old woman, a case study reports. Her symptoms, including tongue ... Read more

December 2, 2021December 2, 2021

BioCryst Raises $350M to Support Orladeyo’s Global Launch

Angioedema News

BioCryst Pharmaceuticals has received funds worth $350 million that will be used in part to support the global launch of Orladeyo (berotralstat), an oral therapy to prevent hereditary angioedema (HAE) ... Read more

November 29, 2021November 29, 2021

Australia Adds Takhzyro to Its Benefits Scheme on Dec. 1

Angioedema News

Starting on Dec. 1, people with hereditary angioedema (HAE) in Australia will have access to Takhzyro (lanadelumab), an under-the-skin injection to prevent HAE swelling attacks, through Australia’s Pharmaceutical Benefits Scheme (PBS). ... Read more

November 22, 2021November 22, 2021

Ionis Launches Phase 3 Trial of Donidalorsen for Preventing Attacks

Angioedema News

Ionis Pharmaceuticals has launched a registrational Phase 3 clinical trial to evaluate the safety and effectiveness of its investigational therapy donidalorsen, formerly known as IONIS-PKK-LRx, in people with hereditary angioedema ... Read more

November 18, 2021November 18, 2021

Pharvaris Seeks Trial Patients to Test Its Oral Therapy for HAE Attacks

Angioedema News

Pharvaris is actively recruiting people with hereditary angioedema (HAE) types 1 or 2 for two clinical trials testing its investigational oral therapy PHVS416 as either an on-demand or prophylactic (preventive) ... Read more